Back to Search
Start Over
Single-domain antibodies as therapeutics for solid tumor treatment.
- Source :
-
Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2024 Jul; Vol. 14 (7), pp. 2854-2868. Date of Electronic Publication: 2024 Mar 15. - Publication Year :
- 2024
-
Abstract
- Single-domain antibodies (sdAbs), initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs, have emerged as a promising alternative to conventional therapeutic antibodies. These sdAbs have many superior physicochemical and pharmacological properties, including small size, good solubility and thermostability, easier accessible epitopes, and strong tissue penetration. However, the inherent challenges associated with the animal origin of sdAbs limit their clinical use. In recent years, various innovative humanization technologies, including complementarity-determining region (CDR) grafting or complete engineering of fully human sdAbs, have been developed to mitigate potential immunogenicity issues and enhance their compatibility. This review provides a comprehensive exploration of sdAbs, emphasizing their distinctive features and the progress in humanization methodologies. In addition, we provide an overview of the recent progress in developing drugs and therapeutic strategies based on sdAbs and their potential in solid tumor treatment, such as sdAb-drug conjugates, multispecific sdAbs, sdAb-based delivery systems, and sdAb-based cell therapy.<br />Competing Interests: The authors declare no conflicts of interest.<br /> (© 2024 The Authors.)
Details
- Language :
- English
- ISSN :
- 2211-3835
- Volume :
- 14
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Acta pharmaceutica Sinica. B
- Publication Type :
- Academic Journal
- Accession number :
- 39027249
- Full Text :
- https://doi.org/10.1016/j.apsb.2024.03.016